Tag: Pharmaceutical

Categories
Business

P360 introduces Swittons smart devices for life sciences enterprises

P360’s new lineup of IoT powered smart devices enables omnichannel workflows

PISCATAWAY TOWNSHIP, N.J.–(BUSINESS WIRE)–#EnterpriseTechnology—P360 today announced that its Swittons Internet of Things (IoT) powered smart devices now feature expanded enterprise-level capabilities for life sciences companies. The Swittons platform can now be utilized across several functions within the same organization, with workstream-specific customizations for each functional vertical. Of the many use cases; for example, Swittons can now be used to automate processes between pharmaceutical labs, supply chains and sales teams at the click of a button.


“Unlike multichannel solutions, which operate in silos by nature, omnichannel platforms like Swittons deliver a consistent, personalized user experience across all channels,” stated P360 CEO and Founder Anupam Nandwana. “Coupled with Microsoft foundational software elements, which provides seamless integrations across various user groups, the new Swittons package provides an advanced enterprise solution for sophisticated companies with multiplexed needs.”

The primary drivers of the Swittons omnichannel enterprise revolution are life sciences digital innovation initiatives, the post-COVID-19 business environment and increasingly constrictive regulatory matters regarding direct physician-to-pharma communication.

The original Swittons design was focused on pharmaceutical commercial settings, where the smart devices help streamline remote physician engagement by automating frequent requests and triggering communication channels. The expansion into omnichannel enterprise applications has garnered interest (from various major pharmaceutical companies) for the following cross-pharma use cases:

  • Pharma Labs, where Swittons fills the gaps between scientists and e-systems, by automating functions like opening tickets in service software (ServiceNow, Saleforce Service Cloud, Microsoft Dynamics), activating emergency alerts, automating reagent reorders and triggering team messaging (emails and texts) and phone and video calls.
  • Pharma Supply Chains, where Swittons serves as a connecting point to allow for remote communication, instant notifications and restocking of various warehouses (or pharmacy distribution centers) at the click of a button.
  • Clinical Trials, where Swittons can be situated at the clinical sites to enable one-touch requests of drug supply, incidentals, or trigger discussions with clinical research associates (CRAs).

All of these seemingly independent use cases are actually able to integrate with organization-wide analytics and AI, helping assimilate relevant data to the C-suite. This enables a top-down, multi-tiered workstream of automations to occur within existing enterprise software solutions. This omnichannel approach to software integration allows for direct, human-to-digital information flow across previously siloed systems.

Each Swittons device can be custom branded and programmed to align with specific workstreams, and can integrate with existing IT systems and enterprise platforms such as enterprise resource planning (ERP), customer relationship management (CRM), enterprise asset management (EAM), clinical trial management systems (CTMS), product lifecycle management (PLM) systems, and others. The devices can even trigger phone and video calls via a built-in integration with Microsoft Teams and other virtual communication platforms.

Swittons devices are built on Microsoft Azure, and each device comes out of the box ready and automatically connects through a Wi-Fi or GSM cellular connection. The Swittons platform also features a flexible user portal that includes device usage dashboards and advanced, customizable analytics built on a Microsoft PowerBI foundation.

More information about Swittons is available HERE.

Swittons is powered by the technology and expertise developed by P360. Delivering a 360-view through the pharma, physician, laboratory and patient ecosystem, P360 designs and deploys capabilities that ensure the highest efficiencies and returns on sales operations, data management, clinical trials, patient centricity and IoT innovation. To learn more about P360, visit P360.com.

About Swittons

Based in Piscataway Township, New Jersey, and powered by P360, Swittons is an end-to-end enterprise IoT solution for commercial acceleration. From dashboard to device to data, Swittons powers seamless engagement. Swittons for physicians and pharma is changing everything about how businesses communicate. To learn more, visit Swittons.com.

Contacts

Brian Fitzgerald

Brian.Fitzgerald@P360.com
808-754-0437

Categories
Business

P360 listed as a sample vendor in Gartner’s Hype Cycle for Life Science Commercial Operations, 2020

P360 was recognized as a vendor under the Life Science Sales Performance Management category in the 2020 report

PISCATAWAY TOWNSHIP, N.J.–(BUSINESS WIRE)–#Gartner—P360, a leading developer of technology for life sciences companies, today announced that it has been identified as a Sample Vendor in the Gartner Hype Cycle for Life Science Commercial Operations, 2020. P360 was named Sample Vendor in the Life Science Sales Performance Management (LSSPM) category.[1] As per the report, “LSSPM tools apply technology to streamline the sales operation processes through automation, intuitive workflows, advanced analytics and cloud-based connectivity.”


“P360’s solutions are built to streamline and accelerate sales operations for pharmaceutical commercial organizations, enabling them to work more efficiently and effectively,” stated P360 CEO and Founder Anupam Nandwana. “Swittons, our IoT powered smart devices for life sciences organizations, are a great example of the innovative solutions we develop. We believe in our solution’s value to our customers.”

Earlier this year, P360 launched its industry first IoT product Swittons as a platform for life sciences digital transformation initiatives. Swittons devices are an essential part of any advanced analytics and AI deployment. By integrating with existing systems and collecting data from sources across the enterprise, Swittons help automate messaging and other functions by utilizing push/pull data streams. Each device can be customized to align with specialized workflows, and can be used to authenticate via biometric and RFID models.

Swittons can be configured for labs, biotech organizations and medical device companies. They are also designed to be compatible with existing commercial infrastructure and integrate seamlessly with leading CRM and ERP systems. The devices, which can be custom branded, come programmed to execute up to four different predefined functions.

Bringing critical data from a device to the enterprise has never been easier, because Swittons takes care of all the complex technical work. To learn more about Swittons, simply visit Swittons.com.

Swittons is powered by the technology and expertise developed by P360. Delivering a 360 view through the pharma, physician and patient ecosystem, P360 designs and deploys capabilities that ensure the highest efficiencies and returns on sales operations, data management, clinical trials, patient centricity and IoT innovation. With expertise in supporting commercial operations for companies of all sizes, P360 has built an industry-leading platform that gives customers ownership of their data and the ability to leverage artificial intelligence and machine learning capabilities.

In addition to being listed as a sample vendor in Gartner’s Hype Cycle report, Swittons and P360 CEO Anupam Nandwana was recently named to the PharmaVoice 100, which recognize the most inspirational, motivational and transformational individuals throughout the life-sciences industry.

To learn more about P360, visit P360.com.

[1] Gartner, “Hype Cycle for Life Science Commercial Operations,” Animesh Gandhi, Michael Shanler, August 6, 2020.

Gartner Disclaimer:

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s Research and Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Swittons

Based in Piscataway Township, New Jersey, and powered by P360, Swittons is an end-to-end enterprise IoT solution for commercial acceleration. From dashboard to device to data, Swittons powers seamless engagement. Swittons for physicians and pharma is changing everything about how businesses communicate. To learn more, visit Swittons.com.

About P360

Based in Piscataway Township, New Jersey, P360 is a leading developer of technology for the life sciences industry. Product offerings include BirdzAI, PatientJourney360, Data360, Trials360 and Swittons. To learn more about P360, visit P360.com.

Contacts

Brian Fitzgerald

Brian.Fitzgerald@P360.com
808-754-0437

Categories
Business

Statement in response to news of the indictment of Teva USA

TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Today Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) is responding to news reports detailing that a federal grand jury in Philadelphia, Pennsylvania has returned a criminal indictment charging Teva USA with three counts of antitrust violations under the Sherman Act.

Teva is deeply disappointed that the government has chosen to proceed with this prosecution. The Company has been investigating this matter for over four years and has concluded that Teva did not participate in price fixing. Based on our internal review, Teva firmly rejects the allegations and will vigorously defend the Company in court. Teva has fully cooperated throughout the course of the Department of Justice (DOJ) investigation and has attempted to reach a resolution in the best interest of the Company, its stakeholders and the patients the company serves. The DOJ has shown an unwillingness to consider alternatives that would not deeply impact Teva and the stakeholders who depend on the Company, including the patients who benefit from our medicines.

As we defend this matter, Teva will maintain focus on its critical role in the U.S. healthcare system, ensuring access to affordable medicines, including helping millions of patients who suffer multiple chronic conditions. One out of every 10 of the 3.69 billion generic prescriptions written in the United States each year is filled with a Teva product.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding criminal charges filed by the DOJ against Teva USA, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • our ability to successfully defend against the DOJ criminal charges;
  • the potential impact the DOJ criminal charges, and a potential criminal conviction, may have on our business and operations in general, including our ability to defend and reach a favorable resolution of the civil, private and other litigations related to this matter, the effects on our current indebtedness and our ability to incur additional indebtedness, engage in additional transactions, make new investments, and our ability to continue to do business with governmental bodies in the United States;
  • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally-administered alternatives; the uncertainty of commercial success of AJOVY® or AUSTEDO®; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; ability to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
  • our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our customers and suppliers; adequacy of and our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our restructuring plan announced in December 2017; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; our prospects and opportunities for growth if we sell assets and potential difficulties related to the operation of our new global enterprise resource planning (ERP) system;
  • compliance, regulatory and litigation matters, including: increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time including due to modified government operations due to the COVID-19 pandemic and effects on product and patent approvals; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Quarterly Reports on Form 10-Q for the first and second quarters of 2020 and our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Contacts

IR Contacts
United States
Kevin C. Mannix (215) 591-8912

Israel
Yael Ashman 972 (3) 926-7516

PR Contacts
United States
Kelley Dougherty (973) 832-2810

Israel
Yonatan Beker 972 (54) 888 5898

Categories
Healthcare

Swittons introduces smart IoT devices for pharmaceutical lab digital transformation initiatives

PISCATAWAY TOWNSHIP, N.J.–(BUSINESS WIRE)–#IoT—Swittons, a P360 company, today announced a new line of Internet of Things (IoT) enabled smart devices built specifically for pharmaceutical labs. The fully customizable devices align with strategic Lab of the Future (LoTF) initiatives and help automate various laboratory workflows between people and existing digital lab equipment, systems and solutions. Built on an agile technology platform, Swittons devices are easy to deploy within pharmaceutical laboratories of all types.


“There are profound changes taking place in the area of life science research and development,” stated Swittons CEO and Founder Anupam Nandwana. “Driven by technological advances and the development of precision medicines, these modernization initiatives are designed to propel laboratory efficiencies into the future, allowing scientists to spend more time on science. This has changed the very concept of what the lab is, and Swittons is a key part of that evolution.”

The Swittons software platform is designed to provide life sciences companies with a modern, flexible user interface that not only integrates with other systems, but other IoT devices as well. This flexibility gives labs the power to create their own LoTF, configured in the way that works best for their specific use case. This means Swittons devices can be uniquely programmed, even within an individual laboratory, so end users aren’t forced into workflows that don’t fit their job function. In addition, the devices take up very little desk space, so they are conveniently available and work seamlessly within individual work styles.

Swittons devices are designed to be compatible with existing IT systems and integrate with lab support platforms and services such as LIMS, eDOC and ticketing systems. Swittons also features a powerful backend portal and reporting system, where administrators can view user CLICKS in one convenient location. The devices are even able to trigger phone and video calls via a built-in integration with Microsoft Teams.

Each Swittons device can be custom branded, and programmed for a wide range of laboratory scenarios. In pharmaceutical lab settings, Swittons fills the gap between the scientist and the lab by automating functions such as:

  • Trigger equipment maintenance
  • Open equipment service ticket
  • Indicate equipment availability
  • Trigger a video call
  • Notify of temperature control deviation
  • Notify of spill/cleaning needed
  • Equipment occupancy notification
  • Open Tickets in service software such as ServiceNow, Salesforce Service Cloud, Microsoft Dynamics
  • Reorder reagents
  • Re-stock disposable supplies
  • Report OOS or Aberrant result
  • Summon a lab runner
  • Open SOP software
  • Alert in an emergency

Swittons is built on Microsoft Azure, and each device comes out of the box ready and automatically connects through a Wi-Fi or GSM cellular connection. More information about Swittons for LoTF initiatives is available HERE.

Swittons is powered by the technology and expertise developed by P360. Delivering a 360-view through the pharma physician, laboratory and patient ecosystem, P360 designs and deploys capabilities that ensure the highest efficiencies and returns on sales operations, data management, clinical trials, patient centricity and IoT innovation. To learn more about P360, visit P360.com.

About Swittons

Based in Piscataway Township, New Jersey, and powered by P360, Swittons is an end-to-end enterprise IoT solution for commercial acceleration. From dashboard to device to data, Swittons powers seamless engagement. Swittons for physicians and pharma is changing everything about how businesses communicate. To learn more, visit Swittons.com.

Contacts

Brian Fitzgerald

Brian.Fitzgerald@P360.com
808-754-0437

Categories
Healthcare

Bayer names Lori Moore as vice president, head of U.S. Pharmaceutical Communications

WHIPPANY, N.J.–(BUSINESS WIRE)–Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today.


Moore spent the last six years in senior communications roles at Deloitte, most recently as the Managing Director leading efforts to transform internal communications. Prior to joining Deloitte, Moore served in communications leadership positions at Novo Nordisk and Sanofi. In her new role at Bayer, Moore will be responsible for developing and executing external and internal communication strategies for the company’s pharmaceutical portfolio in the United States, with a specific emphasis on cardiology, oncology, women’s health, hematology and radiology.

Moore officially starts today and will be based in Whippany, N.J. She will report directly to Raymond F. Kerins, Jr., Senior Vice President of Corporate Affairs, and serve on the U.S. Corporate Affairs and Pharmaceutical Leadership Teams.

“I’m delighted to have Lori join the Bayer team as she brings more than 20 years of experience in the pharmaceutical industry,” Kerins said. “Her impressive knowledge and expertise will help us advance our communications about the company’s pharmaceutical business here in this country.”

Throughout her career, Moore has served in various positions leading marketing communications, corporate branding, internal communications and public relations. In her most recent role, she was responsible for transforming and implementing a new internal communications strategy to support the business needs at Deloitte. Earlier, she served as the head of communications for Deloitte’s audit and risk advisory business.

Prior to her time at Deloitte, Moore spent nine years at Novo Nordisk as the Executive Director for Communications and Public Affairs, where she oversaw all strategic communications, including brand and reputation management, crisis management and employee engagement in the United States. Earlier in her career, Moore managed the Global Product communications for Sanofi where she was responsible for the communications around product launches, programs and issues management.

“I’m honored to join the Bayer team at such a critical time of growth for the division,” Moore said. “Bringing innovative medicines to market is at the heart of what we do, and I look forward to communicating this important story with patients, physicians and providers throughout the United States.”

Moore holds a Master of Science degree in Communications from Northwestern University and a Bachelor of Arts in Journalism from Northern Illinois University.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.us.

Social Media Channels

– Facebook: BayerUnitedStates
– Twitter: BayerUS
– Instagram: BayerUS
– YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Carolyn Nagle

Bayer U.S.

Email: carolyn.nagle@bayer.com
Mobile: 201-419-0337